Merck: Keytruda success in pleural cancer
(CercleFinance.com) - Merck announced on Friday that its blockbuster Keytruda immunotherapy, combined with chemotherapy, improved survival in patients with advanced malignant pleural mesothelioma.
In a phase 2/3 clinical trial conducted in France and Italy, the drug combined with chemotherapy resulted in a "statistically significant" improvement in the overall survival of patients compared to chemotherapy alone, according to the trial's interim results.
Malignant pleural mesothelioma is a rapidly progressing cancer that develops in the lining of the lungs and has a poor prognosis. This cancer of the pleura is often caused by exposure to asbestos.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
In a phase 2/3 clinical trial conducted in France and Italy, the drug combined with chemotherapy resulted in a "statistically significant" improvement in the overall survival of patients compared to chemotherapy alone, according to the trial's interim results.
Malignant pleural mesothelioma is a rapidly progressing cancer that develops in the lining of the lungs and has a poor prognosis. This cancer of the pleura is often caused by exposure to asbestos.
Copyright (c) 2023 CercleFinance.com. All rights reserved.